About
Imbiologics is a biotechnology company specializing in the development of innovative immunomodulatory antibody drugs targeting autoimmune diseases and immuno-oncology using their proprietary antibody modality technology IM-OpDECon.
Explore Imbiologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.